To date, the only nAChR PAM commercially available for human use is the acetylcholinesterase (AChE) inhibitor galantamine, approved by the Food and Drug Administration for the treatment of mild to moderate Alzheimer’s disease. This evidence concerns the gene CHRNA4 and early-onset autosomal dominant Alzheimer disease.